Zidovudine and other nucleoside analogue reverse transcriptase inhibitors (NRTIs), like zalcitabine and didanosine used for treatment of individuals infected with HIV-1, can select for viruses with Q151M and other associated mutations (for example, A62V, S68G, V75I, F77L, F116Y) in the reverse transcriptase (RT) enzyme. These mutations confer resistance to multiple nucleoside analogues, and thereby compromise the efficacy of this class of drugs. Presently available phenotypic assays for detection of multiple nucleoside analogue resistant (MNR) HIV-1 require testing for each NRTI individually. Here we report an enzymatic RT assay that uses resistance to zidovudine triphosphate (zidovudine-TP) as a diagnostic biochemical marker of MNR HIV-1. This assay exploits the different biochemical mechanisms for zidovudine-resistance conferred by either Q151M or T215Y/F mutations and the inability of conventional RT assays to detect T215Y/F-associated zidovudine resistance. The assay detects RT activity directly in plasma by using Amp-RT, an ultra-sensitive PCR-based RT assay. We show that enzymatic resistance to zidovudine-TP is specific to MNR RT and is distinguishable from both wild-type (WT) and RT containing classical zidovudine-resistant mutations (D67N, K70R, T215Y/F, K219Q). Compared to WT, MNR HIV-1 RT had 5- to 36-fold increases in the concentration of drug required to inhibit 50% (IC50) of RT activity, depending on the presence of Q151M alone or with additional MNR mutations. A screening assay utilizing 1 μM zidovudine-TP was developed and validated on 14 reference isolates, 37 plasma specimens, and seven patient-derived viruses. Twenty-three specimens were found to have reduced susceptibility to zidovudine-TP, and all had Q151M. In contrast, 21 specimens were sensitive to zidovudine-TP, of which 12 had WT genotypes, four had T215Y/F, and five had T69S-insertions along with T215Y/F mutations. This RT-based phenotypic assay provides a specific and rapid tool for the direct identification and monitoring of Q151M-associated MNR HIV-1 in plasma.
References
1.
CarpenterC.C., CooperD.A., FischlM.A., GatellJ.M., GazzardB.G., HammerS.M., HirschM.S., JacobsenD.M., KatzensteinD.A., MontanerJ.S., RichmanD.D., SaagM.S., SchechterM., SchooleyR.T., ThompsonM.A., VellaS., YeniP.G., & VolberdingP.A.Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Journal of American Medical Association2000; 283: 381–390.
2.
ShirasakaT., YarchoanR., O'BrienM.C., HussonR.N., AndersonB.D., KojimaE., ShimadaT., BroderS., & MitsuyaH.Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proceedings of the National Academy of Sciences USA1993; 90: 562–566.
3.
UenoT., ShirasakaT., & MitsuyaH.Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2’,3′-dideoxynucleoside 5′-triphosphates. Journal of Biological Chemistry1995; 270: 23605–23611.
4.
KavlickM.F., WyvillK., YarchoanR., & MitsuyaH.Emergence of multi-dideoxynucleoside-resistant human immunodeficiency virus type 1 variants, viral sequence variation, and disease progression in patients receiving antiretroviral chemotherapy. Journal of Infectious Diseases1998; 177: 1506–1513.
5.
SchmitJ.C., Van LaethemK., RuizL., HermansP., SprecherS., SonnerborgA., LealM., HarrerT., ClotetB., ArendtV., LissenE., WitvrouwM., DesmyterJ., De ClercqE., & VandammeA.M.Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS1998; 12: 2007–2015.
6.
Van LaethemK., WitvrouwM., BalzariniJ., SchmitJ.C., SprecherS., HermansP., LealM., HarrerT., RuizL., ClotetB., Van RanstM., DesmyterJ., De ClercqE., & VandammeA.M.Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir. AIDS2000; 14: 469–471.
7.
MillerM.D., MargotN.A., HertogsK., LarderB., & MillerV.Antiviral activity of tenofovir (PMPA) against nucleoside-resistant clinical HIV samples. Nucleosides Nucleotides Nucleic Acids2001; 20: 1025–1028.
8.
ShaferR., IversenA., WintersM., AguinigaE., KatzensteinD., & MeriganT.Drug resistance and heterogeneous long-term virologic responses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combination therapy. The AIDS Clinical Trials Group 143 Virology Team. Journal of Infectious Diseases1995; 172: 70–78.
9.
SchmitJ.C., CogniauxJ., HermansP., Van VaeckC., SprecherS., Van RemoortelB., WitvrouwM., BalzariniJ., DesmyterJ., De ClercqE., & VandammeA.M.Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases1996; 174: 962–968.
10.
MaedaY., VenzonD., & MitsuyaH.Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. Journal of Infectious Diseases1998; 177: 1207–1213.
11.
Van VaerenberghK., Van LaethemK., AlbertJ., BoucherC.A., ClotetB., FloridiaM., GerstoftJ., HejdemanB., NielsenC., PannecouqueC., PerrinL., PirilloM. F., RuizL., SchmitJ.C., SchneiderF., SchoolmeesterA., SchuurmanR., StellbrinkH.J., StuyverL., Van LunzenJ., Van RemoortelB., Van WijngaerdenE., VellaS., WitvrouwM., YerlyS., De ClercqE., DestmyerJ., & VandammeA.M.Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues. Antimicrobial Agents and Chemotherapy2000; 44: 2109–2117.
12.
LarderB., DarbyG., & RichmanD.HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science1989; 243: 1731–1734.
13.
MourouxM., IzopetJ., DescampsD., DelaugerreC., Yvon-GroussinA., AngleraudF., CoutellierA., BonmarchandM., ValantinM.A., MatheronS., AgutH., KatlamaC., Brun-VezinetF., & CalvezV.Conditions of “thymidine analog mutations” (TAMs) in naive patients treated with different combinations of d4T. Pathology Biology2000; 48: 508–512.
14.
WintersM.A., CoolleyK.L., GirardY.A., LeveeD.J., HamdanH., ShaferR.W., KatzensteinD.A., & MeriganT.C.A 6-base pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation1998; 102: 1769–1775.
15.
LarderB.A., BloorS., KempS.D., HertogsK., DesmetR.L., MillerV., SturmerM., StaszewskiS., RenJ., StammersD.K., StuartD.I., & PauwelsR.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents and Chemotherapy1999; 43: 1961–1967.
16.
de JongJ.J., GoudsmitJ., LukashovV.V., HillebrandM.E., BaanE., HuismansR., DannerS.A., ten VeenJ.H., de WolfF., & JurriaansS.Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS1999; 13: 75–80.
17.
MasA., PareraM., BrionesC., SorianoV., MartinezM.A., DomingoE., & Menendez-AriasL.Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO Journal2000; 19: 5752–5761.
18.
UenoT., & MitsuyaH.Comparative enzymatic study of HIV-1 reverse transcriptase resistant to 2’,3′-dideoxynucleotide analogs using the single-nucleotide incorporation assay. Biochemistry1997; 36: 1092–1099.
19.
Sluis-CremerN., ArionD., & ParniakM.A.Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cellular and Molecular Life Sciences2000; 57: 1408–1422.
20.
ArionD., KaushikN., McCormickS., BorkowG., & ParniakM.Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase. Biochemistry1998; 37: 15908–15917.
21.
MeyerP., MatsuuraS., MianA., SoA., & ScottW.A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase. Molecular Cell1999; 4: 35–43.
22.
LennerstrandJ., HertogsK., StammersD., & LarderB.Correlation between viral resistance to zidovudine (AZT) and resistance at the reverse transcriptase level found for a panel of HIV-1 mutants. Journal of Virology2001; 75: 7202–7205.
23.
LaceyS.F., ReardonJ.E., FurfineE.S., KunkelT.A., BebenekK., EckertK.A., KempS.D., LarderB.A.Biochemical studies on the reverse transcriptase and RNase H activities from human immunodeficiency virus strains resistant to 3′-azido-3′-deoxythymidine. Journal of Biological Chemistry1992; 267: 15789–15794.
24.
CarrollS., GeibJ., OlsenD., StahlhutM., ShaferJ., & KuoL.Sensitivity of HIV-1 reverse transcriptase and its mutants to inhibition by azidothymidine triphosphate. Biochemistry1994; 33: 2113–2120.
25.
KerrS.G., & AndersonK.S.Pre-steady-state kinetic characterization of wild type and 3′-azido-3′-deoxythymidine (AZT) resistant human immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed DNA polymerization in the mechanism of AZT resistance. Biochemistry1997; 36: 14064–14070.
26.
KrebsR., ImmendorferU., ThrallS., WohrlB., & GoodyR.Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC. Biochemistry1997; 36: 10292–10300.
27.
HirschM.S., Brun-VezinetF., D'AquilaR.T., HammerS.M., JohnsonV.A., KuritzkesD.R., LovedayC., MellorsJ.W., ClotetB., ConwayB., DemeterL.M., VellaS., JacobsenD.M., & RichmanD.D.Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society–USA Panel. Journal of the American Medical Association2000; 283: 2417–2426.
28.
The EuroGuidelines Group for HIV Resistance. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. The EuroGuidelines Group for HIV resistance. AIDS2001; 16: 309–320.
29.
HirschM.S., ConwayB., D'AquilaR.T., JohnsonV.A., Brun-VezinetF., ClotetB., DemeterL.M., HammerS.M., JacobsenD.M., KuritzkesD.R., LovedayC., MellorsJ.W., VellaS., & RichmanD.D.Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. Journal of the American Medical Association1998; 279: 1984–1991.
30.
Garcia LermaJ., SchinaziR.F., JuodawlkisA.S., SorianoV., LinY., TattiK., RimlandD., FolksT.M., & HeneineW.A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). Antimicrobial Agents and Chemotherapy1999; 43: 264–270.
31.
Vazquez-RosalesG., Garcia LermaJ.G., YamamotoS., SwitzerW.M., HavlirD., FolksT.M., RichmanD.D., & HeneineW.Rapid screening of phenotypic resistance to nevirapine by direct analysis of HIV type 1 reverse transcriptase activity in plasma. AIDS Research and Human Retroviruses1999; 15: 1191–1200.
32.
HeneineW., YamamotoS., SwitzerW.M., SpiraT.J., & FolksT.M.Detection of reverse transcriptase by a highly sensitive assay in sera from persons infected with human immunodeficiency virus type 1. Journal of Infectious Diseases1995; 171: 1210–1216.
33.
YamamotoS., FolksT., & HeneineW.Highly sensitive qualitative and quantitative detection of reverse transcriptase activity: optimization, validation, and comparative analysis with other detection systems. Journal of Virological Methods1996; 61: 135–143.
34.
Garcia LermaJ.G., YamamotoS., Gomez-CanoM., SorianoV., GreenT.A., BuschM.P., FolksT.M., & HeneineW.Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT. Journal of Infectious Diseases1998; 177: 1221–1229.
35.
Garcia-LermaJ.G., SorianoV., MasA., Quinones-MateuM.E., ArtsE.J., & HeneineW.Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity. Journal of Clinical Microbiology2000; 38: 402–405.
36.
QariS.H., MagreS., Garcia-LermaJ.G., HussainA.I., TakeuchiY., PatienceC., WeissR.A., & HeneineW.Susceptibility of the porcine endogenous retrovirus to reverse transcriptase and protease inhibitors. Journal of Virology2001; 75: 1048–1053.
37.
ShirasakaT., KavlickM.F., UenoT., GaoW.Y., KojimaE., AlcaideM.L., ChokekijchaiS., RoyB.M., ArnoldE., YarchoanR., & MitsuyaH.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences USA1995; 92: 2398–2402.
38.
NguyenM.H., SchinaziR.F., ShiC., GoudgaonN.M., McKennaP.M., & MellorsJ.W.Resistance of human immunodeficiency virus type 1 to acyclic 6-phenylselenenyl- and 6-phenylthiopyrimidines. Antimicrobial Agents and Chemotherapy1994; 38: 2409–2414.
39.
SchinaziR.F., McMillanA., CannonD., MathisR., LloydR.M., PeckA., SommadossiJ.P., St ClairM., WilsonJ., & FurmanP.A.Selective inhibition of human immunodeficiency viruses by racemates and enantiomeres of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine. Antimicrobial Agents and Chemotherapy1992; 36: 2423–2431.
40.
QariS.H., RespessR., WeinstockH., BeltramiE.M., HertogsK., LarderB.A., PetropoulosC.J., HellmannN., & HeneineW.Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. Journal of Clinical Microbiology2002; 40: 31–35.
41.
WeinstockH., RespessR., HeneineW., PetropoulosC.J., HellmannN.S., LuoC.C., PauC.P., WoodsT., GwinnM., & KaplanJ.Prevalence of mutations associated with reduced antiretroviral drug susceptibility among human immunodeficiency virus type 1 seroconverters in the United States, 1993–1998. Journal of Infectious Diseases2000; 182: 330–333.